Banner MD Anderson Cancer Center

Summary

Banner MD Anderson Cancer Center is a medical facility located in Gilbert, Arizona. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Banner MD Anderson Cancer Center is involved with conducting 222 clinical trials across 288 conditions. There are 25 research doctors associated with this hospital, such as Rajneesh Nath, MD, Shakeela Bahadur, Jiaxin Niu, MD, and Lida Mina.

Top PIs

Clinical Trials running at Banner MD Anderson Cancer Center

Colorectal Cancer

Lung Cancer

Skin Cancer

Breast Cancer

Cancer

Bladder Cancer

Acute Myeloid Leukemia

Non-Small Cell Lung Cancer

Multiple Myeloma

Pancreatic Cancer

Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.

Recruiting

2 awards

Phase 3

4 criteria

Amivantamab + FOLFIRI

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Recruiting

2 awards

Phase 3

4 criteria

A2B395 CAR T-Cell Therapy

for Colorectal Cancer

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose

Recruiting

1 award

Phase 1 & 2

4 criteria